Company news

Immutep Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed

October 3, 2024

Immutep receives A$3.6 million French R&D Tax Incentive

September 23, 2024

New Positive Efficacy Data for Efti in Head and Neck Cancer

September 15, 2024

S&P DJI Announces September 2024 Quarterly Rebalance

September 6, 2024

Appendix 4E & 2024 Full Year Statutory Accounts

August 30, 2024

TACTI-003 data selected for oral presentation at ESMO 2024

August 20, 2024

First Participant Dosed in Phase I Study of IMP761

August 13, 2024

Successful Meeting with FDA on Phase III Design in NSCLC

July 21, 2024

Regulatory Clearance received for Phase 1 trial of IMP761

July 16, 2024

Webcast to discuss data presented at ESMO Plenary Session

July 11, 2024

Positive results in TACTI-003 for 1L HNSCC cohort B patients

July 11, 2024

Webcast slides for new Efti clinical data in 1st line HNSCC

June 26, 2024

Positive topline results from ph2b in head & neck cancer

June 26, 2024

Immutep completes underwritten retail entitlement offer

June 24, 2024

Immutep completes institutional pro-rata offer & placement

June 4, 2024

Immutep announces Ph 3 clinical trial collaboration with MSD

June 3, 2024

Immutep Capital Raising Presentation

June 2, 2024

A$100 million fully underwritten equity raising

June 2, 2024

AIPAC-003 safety lead-in data presented at ESMO Breast 2024

May 15, 2024

Positive initial data in phase 2 Soft Tissue Sarcoma trial

May 1, 2024

Positive preliminary topline results from TACTI-003 Cohort B

April 23, 2024

CHDR to conduct first-in-human phase 1 trial of IMP761

April 17, 2024

First Clinical Data announced from 90mg Dosing of Efti

March 5, 2024

PEI provides constructive feedback for ph3 lung cancer trial

December 20, 2023

Immutep receives A$2.6 million French R&D Tax Incentive

December 6, 2023

Immutep Completes Enrolment for TACTI-003 Phase IIb Trial

November 8, 2023

Lead-in phase completed for ph2/3 trial in Breast Cancer

November 5, 2023

New Biomarker Data from TACTI-002 trial in 1st line NSCLC

November 2, 2023

Immutep reports promising data from INSIGHT-003 trial

October 23, 2023

Webcast slides for new Efti clinical data in 1st line NSCLC

October 22, 2023

Excellent Overall Survival in Non-Small Cell Lung Cancer

October 22, 2023

Immutep announces publication of ESMO 2023 abstracts

October 15, 2023

Commercial Scale Manufacturing of Efti for Clinical Trials

September 20, 2023

Appendix 4E & 2023 Full Year Statutory Accounts

August 29, 2023

Immutep receives positive scientific advice from EMA

August 1, 2023

1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial

July 27, 2023

US patent granted for Efti with PD-1 pathway inhibitor

June 27, 2023

Immutep granted US patent for IMP761 agonist LAG-3 antibody

June 20, 2023

A$80 million fully underwritten equity raising

May 30, 2023

Charles River Laboratories to run IMP761 Toxicology Study

May 28, 2023

Publication of Abstracts for ASCO 2023 Annual Meeting

May 25, 2023

1st patient dosed in AIPAC-003 ph2/3 breast cancer trial

May 24, 2023

Promising New Data in 1st line NSCLC from INSIGHT-003 Trial

May 23, 2023

Excellent initial Overall Survival Benefit in 1st line NSCLC

May 16, 2023

FDA supportive of Efti registrational trial in lung cancer

May 15, 2023

Approval to start Efti & Bavencio trial in urothelial cancer

April 30, 2023

Immutep to announce new TACTI-002 data at ASCO 2023

April 26, 2023

Response to ASX Aware Query

April 18, 2023

Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma

April 16, 2023

Positive Final Data in 2nd Line Metastatic NSCLC Patients

March 31, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 112 decks. Every deck is listed under its year.